TD Asset Management Inc. Sells 1,800 Shares of GlycoMimetics Inc (NASDAQ:GLYC)

TD Asset Management Inc. lessened its holdings in GlycoMimetics Inc (NASDAQ:GLYC) by 2.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 74,310 shares of the biotechnology company’s stock after selling 1,800 shares during the period. TD Asset Management Inc. owned 0.17% of GlycoMimetics worth $926,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of GLYC. Virtus ETF Advisers LLC grew its holdings in GlycoMimetics by 3.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 29,862 shares of the biotechnology company’s stock valued at $283,000 after buying an additional 1,057 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of GlycoMimetics by 1.9% during the 4th quarter. Bank of New York Mellon Corp now owns 144,163 shares of the biotechnology company’s stock worth $1,365,000 after purchasing an additional 2,718 shares in the last quarter. Alps Advisors Inc. grew its holdings in shares of GlycoMimetics by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 104,192 shares of the biotechnology company’s stock worth $1,298,000 after purchasing an additional 4,507 shares in the last quarter. BNP Paribas Arbitrage SA acquired a new stake in shares of GlycoMimetics during the 1st quarter worth $88,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in shares of GlycoMimetics by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,748 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 9,175 shares in the last quarter.

GLYC stock traded up $0.42 during mid-day trading on Friday, reaching $11.92. The company’s stock had a trading volume of 420,629 shares, compared to its average volume of 203,296. The company has a market capitalization of $496.58 million, a P/E ratio of -10.10 and a beta of 2.65. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.88 and a current ratio of 23.88. GlycoMimetics Inc has a 12 month low of $8.29 and a 12 month high of $17.78. The business’s 50 day moving average price is $11.71.

GlycoMimetics (NASDAQ:GLYC) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. Research analysts anticipate that GlycoMimetics Inc will post -1.18 earnings per share for the current fiscal year.

GLYC has been the topic of several analyst reports. Zacks Investment Research lowered GlycoMimetics from a “hold” rating to a “sell” rating in a report on Thursday, March 7th. BidaskClub lowered GlycoMimetics from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. Piper Jaffray Companies initiated coverage on GlycoMimetics in a report on Friday, April 12th. They set an “overweight” rating and a $20.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of GlycoMimetics in a report on Friday, April 12th. Finally, Cowen reissued a “buy” rating on shares of GlycoMimetics in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.00.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

See Also: Market Perform

Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.